About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Michigan | 508 Studies

Clinical Trials LymphomaMichigan

Lymphoma Clinical Trials in Michigan

Find 508 clinical trials for lymphoma near Michigan. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Michigan

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 361-380 of 508 trials

TerminatedA Study of CNTY-101 in Participants With CD19-Positive B-Cell MalignanciesELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory…NCT05336409·Gilbert, Arizona and 15 others RecruitingA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsThis is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab…NCT06549595·Huntsville, Alabama and 243 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedYttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing…NCT00062114·Little Rock, Arkansas and 93 others

CompletedMORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaThis phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.NCT01748721·Birmingham, Alabama and 19 others

RecruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who…NCT06717347·Mobile, Alabama and 287 others

Active not recruitingAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialThe purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in…NCT03844048·Tucson, Arizona and 55 others

CompletedA Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsThis clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study.NCT03997968·San Francisco, California and 15 others

CompletedSafety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's LymphomaSummary: As this is an open label study, all patients will receive SDX-105 by 30-60 minute intravenous infusion on day 1 and day 2. Treatment will repeat every 21 days.NCT00069758·Birmingham, Alabama and 16 others

CompletedStudy of Efficacy and Safety of CTL019 in Adult DLBCL PatientsThis is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.NCT02445248·San Francisco, California and 25 others

Active not recruitingSelinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin LymphomaThis phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell…NCT03147885·Detroit, Michigan

CompletedNivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell LymphomaA multicenter trial evaluating the combination of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory…NCT03927105·Ann Arbor, Michigan and 2 others

CompletedCombination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00032019·Anniston, Alabama and 80 others

CompletedStudy To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic DermatitisStudy B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize…NCT02780167·Birmingham, Alabama and 63 others

CompletedRituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell LymphomaThis phase I/II trial studies the side effects and best dose of temsirolimus when given together with cladribine and rituximab and to see how well it works in treating patients…NCT00787969·Scottsdale, Arizona and 143 others

Active not recruitingA Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCLA Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell…NCT02717624·Louisville, Kentucky and 14 others

TerminatedA Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyThe purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not…NCT01232556·Burbank, California and 176 others

RecruitingA Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesThis study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111.NCT06528301·Duarte, California and 8 others

CompletedSWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical TrialRATIONALE: Collecting and storing samples of tissue from patients with non-Hodgkin lymphoma to study in the laboratory may help the study of cancer in the future.NCT00898872·Anchorage, Alaska and 81 others

Active not recruitingEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or…NCT03213652·Birmingham, Alabama and 125 others

CompletedObservational Retrospective Cohort Study of Systemic Therapies for R/R DLBCLTo compare the efficacy outcomes of the L-MIND cohort with the effectiveness in a matched patient population treated with systemic NCCN/ESMO guideline listed regimens administered…NCT04697160·Scottsdale, Arizona and 164 others

PreviousPage 19 of 26Next

Other Conditions in Michigan

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia